Kidney Failure, Chronic Clinical Trial
Official title:
Piloting a Novel Behaviour Change Intervention for Improving Treatment Adherence in Haemodialysis Patients
Helping patient with long-term conditions to make informed decisions about adherence to
their treatment is an important element in facilitating self-management. Estimates of
non-adherence to treatment in people living with long-term conditions are typically high,
averaging at around 50%.This not only impacts negatively on patient outcomes but also places
a significant financial burden on healthcare provision.
While clinical efforts have focused on promoting patient self-management, with some success,
work in Psychology on behaviour change has had little influence on clinical practice. In
this project, the team wish to evaluate the potential for a novel intervention from the
behaviour change literature, self-affirmation, to promote improved fluid control among
non-adherent patients. The intervention works by promoting a patient's sense-of-self
(self-affirmation), which has been shown to modify the patient's acceptance of health-risk
information, their self-efficacy, their intention to change, and subsequently their
behaviour.
A randomised controlled pilot trial is proposed. The trial is designed to build upon routine
education about fluid control during dialysis visits, and will compare a group of patients
who have received an intervention to boost their sense-of-self (self-affirmation arm) to a
control group (control arm). Patients in the self-affirmation arm should have a more
positive evaluation of the health-risk information about fluid management, feel more able
to, and intend to change their fluid control behaviour, and subsequently have lower
interdialytic weight gain.
People living with renal failure have to endure a demanding treatment regimen to keep them
alive including haemodialysis, a restricted diet and fluid intake and multiple drug
treatments. These demands have a profound effect on the patient's quality of life. It is not
surprising that many find it very difficult to manage some treatments even when they are
known to be important for the patient's survival. Restricting fluid intake (often as little
as 500ml per/day) is an essential treatment for many patients with advanced kidney failure
receiving haemodialysis, but many find it difficult to adhere. Estimates of fluid
restriction non-adherence range between 10-70%. Not adhering to the recommended maximum
fluid intake leads to fluid overload, which is associated with pulmonary oedema,
cardiovascular disease and premature death.
Understanding how to help patients improve their treatment adherence is challenging and
multifaceted. A recent Cochrane Review concluded that: "For long-term treatments, no simple
intervention, and only some complex ones, led to improvements in health outcomes.". The
healthcare service has tried to help patients by promoting the patient's own role in their
healthcare and in educating patients about their illness and the treatments. However, it is
widely acknowledged that education alone is insufficient to change a patient's behaviour.
Educating patients about the consequences of non-adherence is often unsuccessful as for some
patients, they have become entrenched in poor health care behaviour over extended periods of
time. In this case, repeated exposure of the patient to threatening health-risk information
might be ineffective as the patient has likely become well rehearsed in discounting the
information being provided, and the behaviour of the patient will not change.
The proposed study is designed to investigate a novel intervention to promote behaviour
change that has been shown to be effective in changing behaviour in public health (e.g.
unhealthy dietary intake, unsafe sun exposure, hazardous drinking and smoking cessation) The
intervention is simple to implement, requires little training of staff and may have major
benefits for the patients and the NHS. The intervention is based on self-affirmation theory.
Central to this body of work is the recognition that most health-risk education confronts
people with information that is threatening, both to survival, and to their sense of self.
The person's response is to interpret the information in a way that reduces the threat to
them, for example by denigrating the veracity of the information. In turn the bias with
which the information is interpreted reduces its ability to change behaviour. The theory
suggests that if the person's sense of their own worth (e.g. sense-of-self) is boosted at
the time of receiving the threatening health-risk message, the person is less likely to
interpret the information in a biased way, rendering them more likely to accept the message,
have increased intention to change and believe that they can (self efficacy), and ultimately
change their behaviour. For example, Armitage examined adults' reactions to alcohol
education materials, and in a randomised controlled trial compared participants who
self-affirmed by completing an experimental questionnaire with participants who completed a
control questionnaire. Self-affirmation not only significantly increased participants'
receptiveness to the message, but also improved the effectiveness of the education in that
29% (27/92) fewer people were engaged in hazardous drinking at the end of the study if they
had self-affirmed.
Until recently, this behaviour change intervention method had not been tested in a patient
group experiencing a long-term condition like renal failure. In a recent pilot study (UKCRN
Portfolio study 74185), the team evaluated the potential for a self-affirmation intervention
to promote improved phosphate medication adherence among non-adherent patients. Interim
results from this study have highlighted key issues for which further research is necessary.
Firstly, this intervention is known to be more effective in people with low motivation and
this informed the recruitment strategy, targeting patients who appeared (on the basis of
high serum phosphate levels) to be non-adherent in taking their phosphate medication.
However, despite the patient sample's higher average phosphate levels, the majority of the
patient group reported to be motivated to improve phosphate control. Therefore, it is likely
that for many of these patients there are other reasons for their higher average phosphate
levels, such as forgetting to take their medication. In the group of patients who did report
low motivation to taking their medication (25% of the sample), the effects of the
self-affirmation were observed. There was a trend for patients who self-affirmed, to report
the health-risk message to be higher quality; greater self-efficacy and intention to improve
phosphate control and ultimately their serum phosphate levels were significantly reduced at
one month compared with the control group. It is important to now test the intervention with
a larger group of patients reporting low motivation towards the required health behaviour.
The team identified another treatment (fluid management) that most renal patients must
follow and evaluated 93 patients' thoughts about managing their fluid intake. The results of
this brief study suggest that a larger proportion of patients are less motivated to manage
their fluid intake and therefore, assessing the feasibility and efficacy of the
self-affirmation intervention would be achievable in this treatment group. Fluid management
is a central adherence issue to address as it is not only clinically very important but it
is a particularly difficult aspect of treatment for patients to manage.
The second issue that arose in the first study is the longevity of the intervention. The
apparent effects of self-affirmation on behaviour change to improve phosphate control
observed at one month were not sustained at three month follow-up which suggests that
self-affirmation might require repeated interventions. An important feature of this new
study would be to include repeated self-affirmations in the intervention group to
investigate this further.
A randomised controlled pilot trial is proposed. The study aims to recruit 120 patients
across a network of dialysis units, focussing on patients who have higher than average
interdialytic weight gains (IDWG). The trial is designed to build upon routine education
about fluid management during dialysis visits, and will compare a group of patients who have
received a self-affirmation intervention to boost their sense-of-self (self-affirmation arm)
to a control group (control arm). It is expected that patients in the self-affirmation arm
should have a more positive evaluation of the health-risk information about fluid
management, feel more able to, and intend to change their fluid control behaviour. The
appropriate methods of analysis include logistic regression, and mixed multilevel models,
but the relatively small sample size will limit the extent of the modelling that can be
undertaken. Thus the aim of the analysis will be examine the size of the observed effects
and to design a larger study. The study will inform the extent to which psychological and
clinical factors contribute to the outcome and should be used in future studies.
As this intervention is targeting non-adherent patients (as defined by higher IDWG levels)
and therefore not necessarily representative of all patients on dialysis, it is important to
establish the true clinical context. Patients who appear to be managing their treatment
well, based on their current clinical measures, might well be highly motivated. However, it
is also possible that some of those patients also experience low motivation, which in time,
as their illness becomes more severe, would be revealed by worsening adherence and clinical
outcomes. Thus, the study also aims to examine the psychological and clinical factors
associated with treatment adherence and non-adherence in a wider patient sample.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT02922361 -
Spending and Outcomes for Complex Medicare Advantage Patients
|
||
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT01930396 -
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
Phase 4 | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
Not yet recruiting |
NCT01674660 -
Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients
|
N/A | |
Completed |
NCT01209403 -
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
|
Phase 4 | |
Not yet recruiting |
NCT01157260 -
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
Completed |
NCT00534144 -
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
|
Phase 1 | |
Completed |
NCT00226902 -
Vascular Reactivity in Kidney Disease Patients
|
N/A | |
Completed |
NCT00382044 -
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
|
N/A | |
Recruiting |
NCT00235287 -
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00006297 -
Risk Factors for CV Disease in a Dialysis Cohort
|
N/A |